Clinical

Dataset Information

0

EMD 525797 in combination with Cetuximab and Irinotecan in k-ras Wildtype Metastatic Colorectal Cancer


ABSTRACT: Primary objectives: The primary objectives are: • To characterize the safety and tolerability profile of repeated administration of different EMD 525797 dose levels in combination with cetuximab and irinotecan in subjects with k-ras WT mCRC after failure of first-line therapy with an oxaliplatin-containing regimen (Safety Part); • To assess the anti-cancer activity of 2 EMD 525797 doses in terms progression-free survival time in subjects with k-ras WT mCRC after failure of first-line therapy with an oxaliplatin-containing regimen (Randomized Part). Primary endpoints: Safety Part: • To characterize the safety and tolerability profile of repeated administration of different EMD 525797 dose levels in combination with cetuximab and irinotecan in subjects with k-ras WT mCRC after failure of first-line therapy with an oxaliplatin-containing regimen. Randomized Part: • To assess the anti-cancer activity of 2 EMD 525797 doses in terms of progression-free survival time in subjects with k-ras WT mCRC after failure of first-line therapy with an oxaliplatin-containing regimen.

DISEASE(S): Metastatic Colorectal Cancer,Subjects With K-ras Wt, Metastatic Colorectal Cancer Who Have Failed A Fist Line Chemotherapy With An Oxaliplatin-containing Regimen Will Be Eligible For This Trial.

PROVIDER: 2526396 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
2023-03-10 | PXD022072 | Pride
| 2369888 | ecrin-mdr-crc
| 2352516 | ecrin-mdr-crc
| 2101702 | ecrin-mdr-crc
| 2526788 | ecrin-mdr-crc
| 2367583 | ecrin-mdr-crc
2006-05-31 | E-MEXP-433 | biostudies-arrayexpress
| 2290288 | ecrin-mdr-crc
| 2086198 | ecrin-mdr-crc